ATLANTA, June 15 /PRNewswire/ -- CorMatrix® Cardiovascular, a medical device company dedicated to developing and delivering unique extracellular matrix (ECM) biomaterial devices that harness the body's innate ability to repair damaged cardiovascular tissue, announced today it has received CE mark for its CorMatrix ECM for Cardiac Tissue Repair. With this designation, CorMatrix is now able to market this product in European Union countries.
"This CE mark will allow surgeons in Europe to expand their use of CorMatrix ECM to patients needing cardiac tissue repair," said Beecher Lewis, President and Chief Operating Officer, CorMatrix. "We believe this additional indication will allow us to significantly expand our presence outside of the United States and drive growth in key markets."
CorMatrix's ECM for Cardiac Tissue Repair is used to repair heart structures during open heart surgery – such as closing a hole in the heart (known as atrial septal defect or ASD). During surgery, CorMatrix ECM is sutured onto the heart tissue in need of repair. It then serves as a scaffold, enabling the body's own cells to infiltrate and ultimately replace and remodel the implanted ECM with native tissue. The anatomy is restored naturally through the course of the body's innate wound healing process. It works differently than other available surgical materials, as CorMatrix ECM allows for repair of damaged tissue without leaving permanent synthetic or foreign materials in the body, which can result in unwanted effects.
"Through my experience using CorMatrix ECM for pericardial
closure procedures, we've seen that it supports native tissue
repair and provides favorable outcomes for patients," said Prof.
Giovanni Ste '/>"/>